TRVI

Healthcare Biotechnology

Trevi Therapeutics, Inc.

$13.69

-0.22 -1.58% today Live

Price History

Not enough data

Price chart data
Date	Price
Oct 5, 2026, live at 2:08 PM ET	13.69

Key Stats

Market Cap

1.95B

Avg Volume

1.93M

EPS

-$0.35

52W High

$20.22

52W Low

$9.28

Div. Yield

0.0%

Analyst Ratings

Buy

Str Buy

Buy

Hold

Sell

Str Sell

Valuation

Forward P/E

-23.73

P/B Ratio

6.07

EV/EBITDA

-28.00

Margins

Gross Margin 0.0%

Operating Margin 0.0%

Net Margin 0.0%

EBITDA Margin 0.0%

Growth & Returns

Return on Equity

(19.7%)

Return on Assets

(13.8%)

Liquidity & Leverage

Current Ratio

37.28

Quick Ratio

36.68

Debt / Equity

0.00

Total Cash

318.87M

Total Debt

605,000

About

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF, and phase 2a clinical trial in patients with refractory chronic cough. Trevi Therapeutics, Inc. has a license agreement with Keenova Therapeutics plc to develop and commercialize products incorporating nalbuphine hydrochloride in various formulations. Trevi Therapeutics, Inc. was incorporated in 2011 and is headquartered in New Haven, Connecticut.